@article {2396, title = {Effective Dose of Cocoa as a Preemptive Analgesic and Anti- Inflammatory Agent Assessed through Pain Scale and Tumor Necrosis Factor Alpha (TNF-α) in an Acute Pain Animal Model}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {October 2024}, pages = {1134-1137}, type = {Research Article}, chapter = {1134}, abstract = {

Background: Pain is a significant issue for 40-50\% of hospital patients, with 10-50\% of acute pain cases potentially progressing to chronic pain. Pain-associated inflammation often involves the release of mediators, including Tumor Necrosis Factor Alpha (TNF-α). Cocoa beans contain polyphenols, catechins, anthocyanidins, and proanthocyanidins, compounds believed to possess analgesic properties. This study aims to assess cocoa{\textquoteright}s potential as an oral preemptive analgesic agent in an acute pain mouse model, with an emphasis on its impact on inflammation through TNF-α levels. Methods: This true experimental study involved 24 male white mice split into four groups: a control group (K0) receiving a placebo, a treatment group receiving 15 mg/kg BW oral paracetamol (Kpct), a treatment group receiving 0.5 mg/g BW cocoa (K1), and a treatment group receiving 1 mg/g BW cocoa (K2). Pain response was measured using TNF-α levels and the von Frey test. The Kruskal-Wallis test and One-Way ANOVA were employed for statistical analysis. Results: Cocoa at doses of 0.5 mg/g BW and 1 mg/g BW substantially reduced TNF-α levels (75.82 {\textpm} 7.77 and 70.79 {\textpm} 11.50, respectively) compared to the control and paracetamol groups (98.22 {\textpm} 14.74 and 92.81 {\textpm} 2.64). On the first day, compared to the control group{\textquoteright}s 1.82 {\textpm} 0.78 von Frey values, the cocoa-treated groups{\textquoteright} values (6.20 {\textpm} 2.72 and 7.63 {\textpm} 4.11) were notably higher. There were no notable variations in von Frey values across the groups on the second day. However, a correlation was found between von Frey values on the first and second days. Conclusion: Cocoa can potentially serve as an effective preemptive analgesic agent, reducing pain and inflammation primarily by reducing TNF-α levels. These results provide validity to the use of cocoa as an alternative therapy in acute pain management.

}, keywords = {Cocoa, Pain, Pain Degree Analgesia, TNF-α}, doi = {10.5530/pj.2024.16.185}, author = {Herry Cahya Fathani and Herdiani Sulistyo Putri and Prananda Surya Airlangga and Christrijogo Sumartono Waloejo and Ira Sari Yudaniayanti and Pudji Lestari} } @article {2408, title = {Transient Receptor Potential Vanilloid 1 in Acute Pain: A Literature Review}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {October 2024}, pages = {1196-1201}, type = {Review Article}, chapter = {1196}, abstract = {

Transient Receptor Potential Vanilloid 1 (TRPV1) is a protein that functions as a non-selective channel receptor that is widely expressed in skin tissue, including keratinocytes, peripheral sensory nerve fibers, and immune cells. Several structural features of TRPV1 are involved in heat-induced activation, where stimulation of TRPV1 elicits a burning sensation, reflecting the receptor{\textquoteright}s important role in pain. A TRPV1- mediated signalling pathway that functions as an endogenous pain resolution mechanism by inducing nuclear translocation of β-arrestin2 to minimize desensitization of μ-opioid receptors (MOR). TRPV1 agonists can reduce pain primarily by interfering with pain nerve conduction. Several TRPV1 antagonist drug candidates have failed in clinical trials because by interfering with the detection of the above-mentioned stimuli, they triggered serious side effects such as hyperthermia and painful impaired heat detection. In the case of agonists, systemic administration causes more severe side effects such as respiratory damage. Therefore, only topical preparations with limited effectiveness have been developed. The TRPV1 agonist capsaicin is currently the only one approved for the treatment of muscle, bone, neuropathic pain and migraine, and is only available as a low-concentration cream or as a transdermal patch.

}, keywords = {Agonis TRPV1, Capsaicin, Pain, transient receptor potential vanilloid 1}, doi = {10.5530/pj.2024.16.196}, author = {Dian Retno Mumpuni and Herdiani Sulistyo Putri and Prananda Surya Airlangga and Christrijogo Sumartono Waloejo} } @article {1358, title = {Potential Activity of Medicinal Plants as Pain Modulators: A Review}, journal = {Pharmacognosy Journal}, volume = {13}, year = {2021}, month = {January 2021}, pages = {248-263}, type = {Review Article}, chapter = {248}, abstract = {

This review aims to demonstrate the relevance that medicinal plants and their promising results have in prevention and treatment of pain. The neurophysiological bases of pain have been analyzed and the potential mechanisms of action have been proposed, it has also been determined that the main experimental models used for the evaluation of the analgesic potential are: acetic acid-induced writhing test, formalin test, hot-plate test, capsaicin-induced nociception, cinnamaldehyde-induced nociception, glutamate-induced nociception, tail{\textendash}flick test and tail immersion test. There are countless medicinal plants with potential analgesic activity, in some of them main responsible compounds for the activity are flavonoids (vitexin, quercetin, naringenin, astragalin, eupatilin), alkaloids (scotanamine B, bullatine A, S-(+)- dicentrine, stephalagine, lappaconitine), terpenoids (p-cymene, thymol, menthol, citronellol, myrcene, carvacrol, linalool) and saponins (siolmatroside I, cayaponoside D, cayaponoside B4, cayaponoside A1); however, all studies have only been carried out up to pre-clinical stages. Therefore, it is recommended to carry out kinetic studies of the most remarkable natural compounds, evaluate mixtures of active compounds for diminishing doses to avoide possible side effects, and continue with clinical studies of medicinal plants whose safety has already been reported.

}, keywords = {Analgesic, Antinociceptive, Extract, Natural product, Pain}, doi = {10.5530/pj.2021.13.35}, author = {Carmen R Silva-Correa and Jorge L Campos-Reyna and V{\'\i}ctor E Villarreal-La Torre and Abhel A Calder{\'o}n-Pe{\~n}a and Mar{\'\i}a V Gonz{\'a}lez Blas and Cinthya L Aspajo-Villalaz and Jos{\'e} L Cruzado-Razco and William Antonio Sag{\'a}stegui- Guarniz and Luz M Guerrero-Espino and Julio H} } @article {887, title = {In vivo Comparative Anti-Inflammatory and Analgesic Activities of Root Bark, Stem and Leaf Extracts of Capparis erythrocarpus (Capparaceae)}, journal = {Pharmacognosy Journal}, volume = {11}, year = {2019}, month = {May 2019}, pages = {515-520}, type = {Original Article}, chapter = {515}, abstract = {

Introduction: The root bark powder of the medicinal plant Capparis erythrocarpus is used at the Centre for Plant Medicine Research (In Ghana) against inflammatory pain disorders. The whole plant is destroyed to obtain the root bark which constitutes only 11.1 \% of the plant. Hence, the plant is going extinct. We therefore sought to evaluate anti-inflammatory and analgesic activities of the root bark, stem and leaf of C. erythrocarpus in order to explore them as substitute(s) anti-inflammatory and analgesic agent to the root bark. Methods: Carrageenan induced paw oedema assay was used to evaluate anti-inflammatory activity. Hot plate and acetic acid induced writhing assays were employed to ascertain analgesic activity. Results: The extracts of the root bark (CRB) and leaf (CL) produced significant (p\<0.05) antiinflammatory activity of 48.93 and 37.42 \% at 50 and 200 mg/kg p.o. respectively whereas the stem extract (CS) was inactive. Moreover, the extracts produced significant (p\<0.05) analgesic activity. The analgesic activity (178.20 {\textendash} 248.70 \%) of the extracts were higher than that of morphine (136.70\%) at 5 mg/kg i.m. in the hot plate assay. CS (200 mg/kg p.o.) produced the highest analgesic activity (54.61\%) among the extracts and diclofenac sodium (41.15\%) at 5 mg/kg p.o. in the writhing assay. Conclusion: These results indicates that the leaf of C. erythrocarpus can be substituted for the root as analgesic and anti-inflammatory agent. Whiles, the stem can also be used as analgesic agent. This will save the plant from extinction.

}, keywords = {Hot plate, Oedema, Pain, Phytochemical constituents, Writhing assay}, doi = {10.5530/pj.2019.11.82}, author = {Emmanuel Kofi Kumatia and Stephen Antwi and Henry Brew-Daniels and Alfred Ampoma Appiah and Augustine Ocloo} }